Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Cablivi 10 mg powder and solvent for solution for injection – Patient Card - Risk Minimisation Information for Patients

Cablivi is subject to additional monitoring. This will allow quick identification of new safety information. If you notice any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

Cablivi 10 mg powder and solvent for solution for injection- Healthcare Professional Letter- Risk Minimisation Information for Healthcare Professionals

Sanofi Genzyme is required to distribute copies of the approved risk minimisation educational material for Cablivi ® (caplacizumab) to relevant healthcare professionals. Caplacizumab, the active ingredient of Cablivi, is a humanised bivalent Nanobody targeting the A1 domain of von Willebrand factor. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.